Upside Research
Contributor since: 2016
Latest Articles
Holiday Gifts For Iconix Investors
Assessing The Iconix News And Stock Drop
Novocure: This Low-Risk, High-Upside Biotech Continues To Roll
Iconix: Different And Far Better Than Traditional Retailers
Iconix Brand Group: Q2 Breakdown
Novavax's Pipeline: Plenty Of Ammunition
Iconix: 8 Catalysts To Light A Fire Under This Highly Undervalued Stock
Iconix: Expansion Of Brands Is Slated To Bring Major Second-Half Growth
Iconix: Hidden Gem On Earnings Call - 65% Boost In Earnings From Amortization Approach
Iconix: Evaluation Of The Big Peanuts Sale, Earnings Call And More
Novavax: Earnings Call Review And Assessment Of The Multi-Arm RSV Trial
Iconix Brand Group: Trump's Tax Plan Would Greatly Increase Annual Earnings
NovoCure: An Under-The-Radar Biotech With Successful New Trials And Revenue Growth, Part 1
Iconix: New Developments And Upcoming Catalysts
Iconix: Assessing The 3rd Quarter Earnings Call And Report
Iconix: Another Quarter Of Progress And Another Probable Beat
Novavax; Part 2: A Deep Dive Into Phase 3 Of Its RSV Vaccine For Older Adults
Novavax: High Probability Of A Huge Gain Within Weeks - Part 1 Of 2
Examining The Longer-Term For Iconix Beyond The Coming Earnings Call
Iconix: Assessment Of The Spring And Preview Of The Next Report (Part 2 Of 2)
Iconix: Assessment Of The Spring And Preview Of The Next Report (Part 1 Of 2)
Iconix Brand Group: Breaking Down The Debt Buyback Agreements
Near-Term Catalysts For Iconix: Part 5: Half-Time Report
Near-Term Catalysts For Iconix; Part 4: The New CEO Plus Cuneo
Near Term Catalysts For Iconix; Part 3: The Approaching Earnings Call
Near-Term Catalysts For Iconix; Part 2: Popping The Default Illusion
4 Near-Term Catalysts For Iconix; Part 1: SEC News
An Evaluation Of Iconix's Poison Pill Plan And Announcement